SonoThera raised $125.45 million to advance the development of it’s clinical pipeline of ultrasound-mediated nonviral genetic medicines for the treatment of muscle, kidney, heart, and CNS diseases, including Duchenne muscular dystrophy and X-linked Alport syndrome, both rare disorders.
